Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.36 |
| ▸ | RARB | P10826 | 3/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22384107 | 0.90 | RARB (0.39) | ITGB3ITGA2BS1PR1RARBENPP2 | |
| SCHEMBL20900636 | 0.87 | ITGB3 (0.41) | ITGB3ITGA2BS1PR1RARBS1PR4 | |
| SCHEMBL22756173 | 0.87 | PPARG (0.42) | ITGB3ITGA2BS1PR1RARBENPP2 | |
| SCHEMBL22384155 | 0.87 | ITGB3 (0.35) | ITGB3ITGA2BS1PR1RARBENPP2 | |
| SCHEMBL22384179 | 0.86 | ITGB3 (0.40) | ITGB3ITGA2BS1PR1RARBPPARG | |
| SCHEMBL16305930 | 0.86 | ITGB1 (0.40) | ITGB3ITGA2BS1PR1RARBPPARG | |
| SCHEMBL22384044 | 0.86 | PPARG (0.35) | ITGB3ITGA2BS1PR1RARBENPP2 | |
| SCHEMBL22384279 | 0.86 | ITGB1 (0.44) | ITGB3ITGA2BENPP2PPARGITGB1 | |
| SCHEMBL20426081 | 0.85 | ITGB3 (0.43) | ITGB3ITGA2BPPARGPPARAITGB1 | |
| SCHEMBL20427250 | 0.85 | ENPP2 (0.36) | ITGB3ITGA2BS1PR1RARBENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259823-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | ITGB3 3678/4885ITGA2B 4134/4885S1PR1 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.